Osteogenicity of biphasic calcium phosphate ceramics and bone autograft in a goat model.
The aim of this work was to compare the osteogenicity of calcium phosphate ceramic granules with autologous bone graft in ectopic and orthotopic sites. Biphasic calcium phosphate (BCP) granules composed of hydroxyapatite (HA) and beta-tricalcium phosphate (beta-TCP) in a 60/40 ratio were sintered at 1050, 1125 and 1200 degrees C, producing different microporosities. Either BCP ceramic granules or autologous bone chips (n=7) were implanted into paraspinal muscles. Osteoinduction was not observed in either the BCP implants or autologous bone chips after 6 or 12 weeks in the ectopic sites. Hollow and bored polytetrafluoroethylene (PTFE) cylinders were filled with autologous bone, BCP granules or left empty, then implanted into critical-sized defects in femoral epiphyses. The PTFE cylinders left empty contained marrow and blood vessels but not mineralized bone, indicating that this model prevented bone ingrowth (0.56+/-0.43% at 12 weeks). Bone formation was observed in contact with the BCP1050 and BCP1125 granules in the femoral sites after 6 weeks. The amount of bone after 12 weeks was 5.6+/-7.3 and 9.6+/-6.6% for BCP1050 and BCP1125, respectively. Very little bone formation was observed with the BCP1200 implants (1.5+/-1.3% at 12 weeks). In both the ectopic and orthotopic sites, autologous bone chips were drastically resorbed (from 19.4+/-3.7% initially to 1.7+/-1.2% at 12 weeks). This study shows that synthetic bone substitutes may have superior stability and osteogenic properties than autologous bone grafts in critical-sized bone defects.
Fellah
Borhane H
BH
INSERM U791, Laboratory for Osteoarticular and Dental Tissue Engineering, Faculty of Dental Surgery, 1 Place Alexis Ricordeau, Nantes, France.
Gauthier
Olivier
O
Weiss
Pierre
P
Chappard
Daniel
D
Layrolle
Pierre
P
D000818:Animals; D001862:Bone Resorption / Q000473:pathology; D018786:Bone Substitutes / Q000494:pharmacology*; D016025:Bone Transplantation; D002130:Calcium Phosphates / Q000494:pharmacology*; D002516:Ceramics / Q000494:pharmacology*; D005260:Female; D005269:Femur / Q000473:pathology / Q000601:surgery; D006041:Goats; D006882:Hydroxyapatites / Q000494:pharmacology; D008422:Materials Testing; D008855:Microscopy, Electron, Scanning; D018482:Muscle, Skeletal / Q000473:pathology / Q000601:surgery; D016348:Osseointegration / Q000187:drug effects; D010012:Osteogenesis / Q000187:drug effects* / Q000502:physiology*; D011138:Polytetrafluoroethylene; D023822:Tissue Engineering; D014182:Transplantation, Autologous
D018786:Bone Substitutes; D002130:Calcium Phosphates; D006882:Hydroxyapatites; C074950:hydroxyapatite-beta tricalcium phosphate; D011138:Polytetrafluoroethylene; C020243:calcium phosphate